This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
BrainsWay is ushering in a new era of brain disorder treatment. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medicine studies, BrainsWay represents the next-generation of treatments for depression, OCD, and other brain disorders, achieving outcomes not thought possible with traditional medical solutions.
BrainsWay Introduces the First FDA Cleared (De-Novo) Non-invasive Medical Device for the Treatment of OCD.
Major Depressive Disorder is a neuropsychiatric disorder that is expressed in emotional, physiological and behavioral effects.
OF POPULATION IS COVERED BY REIMBURSEMENT
Regain your confidence and learn more about BrainsWay’s groundbreaking technology.
Read what patients share about their experience
Literature studies [Bersani et al., 2013] showed theability to treat different neuropsychiatric disorders using H1 coil,one of the coils belongs
In the last few years, deep transcranial magnetic stimulation (dTMS) has been used for the treatment of depressive disorders,which affect
Modulating the function of the insular cortex could be a novel therapeutic strategy to treat addiction to a variety of
Stimulator technology has not changed significantly since the early days of TMS. Stimulation of a single-element coil using the sole